FAQ: Lantern Pharma's AI-Driven Cancer Drug Development Platform
Summary
Lantern Pharma is using its proprietary AI platform RADR® to accelerate cancer drug discovery and development, significantly reducing timelines and costs while advancing multiple clinical-stage oncology programs.
What is Lantern Pharma and what does it do?
Lantern Pharma is an AI-driven cancer drug developer that uses machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications, transforming the cost and timeline of oncology drug development.
How does Lantern Pharma’s AI platform work?
The RADR® platform self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications by leveraging over 200 billion oncology-focused data points and 200+ advanced machine learning algorithms.
What are the main benefits of using AI in cancer drug development according to Lantern Pharma?
AI is compressing development timelines and cost structures across oncology, enabling faster, cheaper, and more personalized treatments while significantly reducing the time and cost of drug development.
What clinical-stage programs does Lantern Pharma currently have?
Lantern has three clinical-stage oncology candidates, including a Phase 2 trial for non-smoker non-small cell lung cancer and a program targeting cancers with DNA damage repair deficiency using synthetic lethality.
What upcoming milestones does Lantern Pharma expect?
The company expects upcoming data milestones from its LP-184 program and plans to roll out its AI platform commercially to drug developers worldwide.
What is the market potential of Lantern Pharma’s pipeline?
The AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and could provide life-changing therapies to hundreds of thousands of cancer patients worldwide.
Where was the CEO interview conducted?
The interview with CEO Panna Sharma was recorded at the New York Stock Exchange and featured on FintechTV.
How can investors get more information about Lantern Pharma?
The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN, and the full interview can be viewed at https://ibn.fm/ZvbMK.
What additional programs does Lantern Pharma’s pipeline include?
The company’s pipeline spans multiple cancer indications including both solid tumors and blood cancers, and includes an antibody-drug conjugate (ADC) program alongside its lead development programs.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 279753